CDK2 and breast cancer: They also consider MITF to be an up-regulator of CDK2 expression and a positive enhancer of cyclin genes CCNB1 and CCND1. CDK2 activity and CDKN2A and CCNB1 overexpression have been consistently linked to breast cancer cell development and survival [35, 36, 37, 38].